Association of Immune-Related Adverse Events With Efficacy of Atezolizumab in Patients With Non–Small Cell Lung Cancer
Mark A. Socinski(Florida Hospital Cancer Institute), Howard West(Vyne Therapeutics (United States))
Cited by 182
Related Papers
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|The Lancet Oncology|2019|1.7k
Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease
|Annals of Neurology|1997|1.5k
Gefitinib versus docetaxel in previously treated non-small-cell lung cancer (INTEREST): a randomised phase III trial
|The Lancet|2008|1.2k
Clinical and pathological correlates of apolipoprotein E ε4 in Alzheimer's disease
|Annals of Neurology|1996|380
Randomized Phase III Trial of Amrubicin Versus Topotecan As Second-Line Treatment for Patients With Small-Cell Lung Cancer
|Journal of Clinical Oncology|2014|344